Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC2A1 | P11166 | 1/20 | 0.47 |
| ▸ | GPR119 | Q8TDV5 | 5/20 | 0.47 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.44 |
| ▸ | PRKDC | P78527 | 1/20 | 0.44 |
| ▸ | STS | P08842 | 1/20 | 0.44 |
| ▸ | BACE1 | P56817 | 1/20 | 0.43 |
| ▸ | CSF1R | P07333 | 1/20 | 0.43 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2169786 | 0.80 | CHEK2 (0.51) | SLC2A1GPR119CHEK2ALDH1A1PIK3CA | |
| SCHEMBL27006948 | 0.77 | SLC2A1 (0.52) | SLC2A1GPR119CHEK2CSF1R | |
| SCHEMBL1526878 | 0.77 | SLC2A1 (0.53) | SLC2A1GPR119CHEK2ALDH1A1STS | |
| SCHEMBL791915 | 0.76 | SLC2A1 (0.63) | SLC2A1GPR119CHEK2ALDH1A1STS | |
| SCHEMBL2244294 | 0.76 | CHEK2 (0.47) | SLC2A1GPR119CHEK2ALDH1A1PIK3CA | |
| SCHEMBL1526855 | 0.76 | SLC2A1 (0.52) | SLC2A1GPR119CHEK2ALDH1A1STS | |
| SCHEMBL2170520 | 0.76 | CHEK2 (0.47) | SLC2A1GPR119CHEK2ALDH1A1PIK3CA | |
| SCHEMBL1526849 | 0.75 | MTNR1A (0.49) | SLC2A1GPR119CHEK2ALDH1A1PIK3CA | |
| SCHEMBL3283198 | 0.75 | SLC2A1 (0.44) | SLC2A1GPR119CHEK2ALDH1A1PIK3CA | |
| SCHEMBL3256200 | 0.75 | GPR119 (0.57) | GPR119CHEK2STSMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040214841-A1 | Quinazoline derivatives for treatment of tumours | ASTRAZENECA AB (SE) | 2004-10-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040214841-A1 | Quinazoline derivatives for treatment of tumours | NQO2, TOP1, TPD52L2 | SLC2A1 1002/4885GPR119 4072/4885CHEK2 715/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.